Drug Type Monoclonal antibody |
Synonyms ANTIGN 109, ANTIGN109 |
Target |
Action antagonists |
Mechanism GnRHR antagonists(Gonadotropin-releasing hormone receptor antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Urogenital Diseases | Preclinical | United States | 30 Jan 2022 | |
Neoplasms | Preclinical | United States | 10 Aug 2020 |